Revision as of 02:54, 4 October 2017

Please feel free to contact us with any questions or inquiries, at the email addresses below.

Editor-in-Chief

Dermatologic Oncology
	Elizabeth Buchbinder, MD Boston, MA LinkedIn	Melanoma
		Merkel cell carcinoma
		Basal cell and squamous cell skin cancer
		Cutaneous T-cell lymphoma
Genitourinary Oncology
Coming soon	Aymen Elfiky, MD, MSc, MBA Boston, MA LinkedIn	Bladder cancer
		Penile cancer
		Prostate cancer
		Renal cancer
		Testicular cancer
Gynecologic Oncology
	Brandon L. Seagle, MD, MS Chicago, IL	Cervical cancer
		Germ cell tumors
		Ovarian cancer
		Uterine cancer
Neuro-Oncology
	Seema Nagpal, MD Palo Alto, CA	Central nervous system (CNS) cancer
		CNS leukemia
		CNS lymphoma
		Glioblastoma
Sarcoma
Coming soon	James L. Chen, MD, MS Columbus, OH LinkedIn	Ewing's sarcoma
		Gastrointestinal stromal tumor
		Osteosarcoma
		Sarcoma (other types)
Thoracic Oncology
	Travis Osterman, DO, MS Nashville, TN Twitter: TravisOsterman LinkedIn	Esophageal cancer
		Mesothelioma
		Non-small cell lung cancer
		Small cell lung cancer
		Thymoma
Myeloproliferative Neoplasms
Coming soon	Sanjay R. Mohan, MD, MSCI Nashville, TN	Chronic myelogenous leukemia
		Chronic myelomonocytic leukemia
		Essential thrombocythemia
		Hypereosinophilic syndrome
		Myelofibrosis
		Polycythemia vera
		Systemic mastocytosis
Plasma Cell Dyscrasias
	Andrew J. Cowan, MD Seattle, WA LinkedIn	Multiple myeloma
		Light-chain (AL) amyloidosis
		Plasma cell leukemia
Transplant
	Aric C. Hall, MD Madison, WI Twitter: AricHall1	Stem cell mobilization
		Allogeneic HSCT conditioning regimens
		Autologous HSCT conditioning regimens
		Graft versus host disease (GVHD)

@@ Line 18: / Line 18: @@
 =Section Editors=
-{| border="1" style="text-align:center;"
+{| border="1" style="text-align:center; width:100%;"
 !colspan="3" align="center" style="color:white; font-size:125%; background-color:#00008B"|'''Dermatologic Oncology'''
 |-
@@ Line 98: / Line 98: @@
 |-
 |rowspan=7|Coming soon
-|rowspan=7|<big>Sanjay R. Mohan, MD, MSCI<br>Nashville, TN</big>
+|rowspan=7|<big>[[User:Sanjaymohan|Sanjay R. Mohan, MD, MSCI]]<br>Nashville, TN</big>
 |[[Chronic myelogenous leukemia]]
 |-
@@ Line 122: / Line 122: @@
 |-
 |[[Plasma cell leukemia]]
+|-
+!colspan="3" align="center" style="color:white; font-size:125%; background-color:#756bb1"|'''Transplant'''
+|-
+|rowspan=4|[[File:Arichall_400x400.jpg|thumb|upright=0.4|center]]
+|rowspan=4|<big>[[User:AricHallMD|Aric C. Hall, MD]]<br>Madison, WI</big><br>Twitter: [https://twitter.com/AricHall1 AricHall1]
+|[[Stem cell mobilization]]
+|-
+|[[Allogeneic HSCT conditioning regimens]]
+|-
+|[[Autologous HSCT conditioning regimens]]
+|-
+|[[Graft versus host disease (GVHD)]]
 |-
 |}